Srikala Sridhar, MD, MSc, FRCPC

Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.

Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.

Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.

The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.

A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.

Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.

A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.

Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.

Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.

Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.